Antitumor actions of baicalein and wogonin in HT-29 human colorectal cancer cells
- Authors
- Kim, So-Jung; Kim, Hyeong-Jin; Kim, Hye-Ri; Lee, Seung-Ho; Cho, Sung-Dae; Choi, Chang-Sun; Nam, Jeong-Seok; Jung, Ji-Youn
- Issue Date
- Dec-2012
- Publisher
- SPANDIDOS PUBL LTD
- Keywords
- apoptosis; baicalein; colon cancer; flavonoid; HT-29; wogonin
- Citation
- MOLECULAR MEDICINE REPORTS, v.6, no.6, pp.1443 - 1449
- Journal Title
- MOLECULAR MEDICINE REPORTS
- Volume
- 6
- Number
- 6
- Start Page
- 1443
- End Page
- 1449
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/15942
- DOI
- 10.3892/mmr.2012.1085
- ISSN
- 1791-2997
- Abstract
- The purpose of this study was to determine the effects of baicalein and wogonin, which are compounds derived from the Chinese herb Scutellaria baicalensis, in suppressing the viability of HT-29 human colon cancer cells. Following treatment with baicalein or wogonin, several apoptotic events were observed, including DNA fragmentation, chromatin condensation and increased cell cycle arrest in the G1 phase. Baicalein and wogonin decreased Bcl-2 expression, whereas the expression of Bax was increased in a dose-dependent manner compared with the control. Furthermore, the induction of apoptosis was accompanied by an inactivation of phosphatidylinositol 3-kinase (PI3K)/Akt in a dose-dependent manner. The administration of baicalein to mice resulted in the inhibition of the growth of HT-29 xenografts without any toxicity following 5 weeks of treatment. The results indicated that baicalein induced apoptosis via Akt activation in a p53-dependent manner in the HT-29 colon cancer cells and that it may serve as a chemopreventive or therapeutic agent for HT-29 colon cancer.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - ETC > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/15942)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.